<DOC>
	<DOCNO>NCT03010176</DOCNO>
	<brief_summary>The purpose study identify maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) MK-1454 alone MK-1454 combination pembrolizumab ( MK-3475 ) participant advanced/metastatic solid tumor lymphomas . MK-1454 administer intratumorally ( IT ) ; pembrolizumab administer intravenously ( IV ) .</brief_summary>
	<brief_title>Study MK-1454 Alone Combination With Pembrolizumab Participants With Advanced/Metastatic Solid Tumors Lymphomas ( MK-1454-001 )</brief_title>
	<detailed_description>Participants receive either MK-1454 monotherapy MK-1454 combination pembrolizumab 35 cycle ( approximately 2 year ) . Participants undergo 24-hour observation period follow first dose administration Cycle 1 , Day 1 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologically cytologicallyconfirmed advanced/metastatic solid tumor lymphoma pathology report receive , intolerant , treatment know confer clinical benefit . Solid tumor lymphomas type eligible enrollment . Has stage III stage IV disease surgically resectable . Has ≥1 injectable lesion amenable injection biopsy measurable . Has ≥1 distant , discrete noninjected lesion amenable biopsy . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Has life expectancy &gt; 3 month . Demonstrates adequate organ function . Female participant childbearing potential must willing use highly effective method birth control surgically sterile , abstain heterosexual activity course study drug 130 day last dose study drug . Male participant reproductive potential must agree use highly effective method contraception sexual contact female childbearing potential start first dose study drug 130 day last dose study drug . Has chemotherapy , definitive radiation , biological cancer therapy within 4 week prior first dose study drug , recover Baseline CTCAE grade 1 adverse event due cancer therapeutic administer &gt; 4 week earlier . Has participate study investigational agent receive study therapy use investigational device within 28 day administration MK1454 . Is expect require form antineoplastic therapy study . Is chronic systemic steroid therapy excess replacement dos ( prednisone ≤ 10 mg/day acceptable ) , form immunosuppressive medication . Has history second malignancy , unless potentially curative treatment complete , evidence malignancy 5 year . Has clinically active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has severe hypersensitivity reaction treatment monoclonal antibody ( mAb ) . Has active autoimmune disease require systemic treatment past 2 year . Has history vasculitis . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis Has undergone prior allogeneic hematopoietic stem cell transplantation within last 5 year . Has know HIV and/or Hepatitis B C infection ( ) . Is pregnant breastfeeding , expect conceive father child within project duration study . Has receive live vaccine within 30 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>